359558332022081520250728
1422-006723152022Aug04International journal of molecular sciencesInt J Mol SciImportance of GLUT Transporters in Disease Diagnosis and Treatment.869810.3390/ijms23158698Facilitative sugar transporters (GLUTs) are the primary method of sugar uptake in all mammalian cells. There are 14 different types of those transmembrane proteins, but they transport only a handful of substrates, mainly glucose and fructose. This overlap and redundancy contradict the natural tendency of cells to conserve energy and resources, and has led researchers to hypothesize that different GLUTs partake in more metabolic roles than just sugar transport into cells. Understanding those roles will lead to better therapeutics for a wide variety of diseases and disorders. In this review we highlight recent discoveries of the role GLUTs play in different diseases and disease treatments.IsmailAbdelrahmanADepartment of Chemistry, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA.TanasovaMarinaM0000-0003-4771-9533Department of Chemistry, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA.Health Research Institute, Michigan Technological University, Houghton, MI 49931, USA.engR15 CA242401CANCI NIH HHSUnited StatesGRANT12736422NHNIH HHSUnited StatesJournal ArticleReview20220804
SwitzerlandInt J Mol Sci1010927911422-00670Glucose Transport Proteins, Facilitative0Membrane Transport Proteins30237-26-4FructoseIY9XDZ35W2GlucoseIMAnimalsBiological TransportFructoseGlucosemetabolismGlucose Transport Proteins, FacilitativegeneticsmetabolismMammalsmetabolismMembrane Transport ProteinsmetabolismGLUT inhibitorsGLUT therapeuticsGLUTsdiagnostic biomarkersmetabolic diseasessugar transportThe authors declare no conflict of interest.202272202272920227302022812113202281360202281660202284epublish35955833PMC936895510.3390/ijms23158698ijms23158698Reckzeh E.S., Waldmann H. Development of Glucose Transporter (GLUT) Inhibitors. Eur. J. Org. Chem. 2020;2020:2321–2329. doi: 10.1002/ejoc.201901353.10.1002/ejoc.201901353PMC721722932421048Boado R.J., Pardridge W.M. The Brain-Type Glucose Transporter Messenger-Rna Is Specifically Expressed at the Blood-Brain-Barrier. Biochem. Bioph. Res. Commun. 1990;166:174–179. doi: 10.1016/0006-291X(90)91927-K.10.1016/0006-291X(90)91927-K2302200Pardridge W.M., Boado R.J., Farrell C.R. Brain-Type Glucose Transporter (Glut-1) Is Selectively Localized to the Blood-Brain-Barrier—Studies with Quantitative Western Blotting and Insitu Hybridization. J. Biol. Chem. 1990;265:18035–18040. doi: 10.1016/S0021-9258(18)38267-X.10.1016/S0021-9258(18)38267-X2211679Farrell C.L., Yang J., Pardridge W.M. GLUT-1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. J. Histochem. Cytochem. 1992;40:193–199. doi: 10.1177/40.2.1552163.10.1177/40.2.15521631552163Nishimura H., Pallardo F.V., Seidner G.A., Vannucci S., Simpson I.A., Birnbaum M.J. Kinetics of Glut1 and Glut4 Glucose Transporters Expressed in Xenopus Oocytes. J. Biol. Chem. 1993;268:8514–8520. doi: 10.1016/S0021-9258(18)52905-7.10.1016/S0021-9258(18)52905-78473295Uldry M., Ibberson M., Hosokawa M., Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 2002;524:199–203. doi: 10.1016/S0014-5793(02)03058-2.10.1016/S0014-5793(02)03058-212135767Nishioka T., Oda Y., Seino Y., Yamamoto T., Inagaki N., Yano H., Imura H., Shigemoto R., Kikuchi H. Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52:3972–3979.1617673Krzeslak A., Wojcik-Krowiranda K., Forma E., Jozwiak P., Romanowicz H., Bienkiewicz A., Brys M. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol. Oncol. Res. POR. 2012;18:721–728. doi: 10.1007/s12253-012-9500-5.10.1007/s12253-012-9500-5PMC334249522270867Kim B.W., Cho H., Chung J.Y., Conway C., Ylaya K., Kim J.H., Hewitt S.M. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J. Transl. Med. 2013;11:185. doi: 10.1186/1479-5876-11-185.10.1186/1479-5876-11-185PMC375066323927384Haber R.S., Rathan A., Weiser K.R., Pritsker A., Itzkowitz S.H., Bodian C., Slater G., Weiss A., Burstein D.E. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer. 1998;83:34–40. doi: 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E.10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E9655290Nagase Y., Takata K., Moriyama N., Aso Y., Murakami T., Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J. Urol. 1995;153:798–801. doi: 10.1016/S0022-5347(01)67725-5.10.1016/S0022-5347(01)67725-57861542Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046–1051. doi: 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7.10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-79305704Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., Penalver M., Mancuso S., Scambia G. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer. 2001;92:1144–1150. doi: 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T.10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T11571727Stewart G.D., Gray K., Pennington C.J., Edwards D.R., Riddick A.C., Ross J.A., Habib F.K. Analysis of hypoxia-associated gene expression in prostate cancer: Lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol. Rep. 2008;20:1561–1567. doi: 10.3892/or_00000180.10.3892/or_0000018019020742Baer S.C., Casaubon L., Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J. Am. Acad. Dermatol. 1997;37:575–577. doi: 10.1016/S0190-9622(97)70174-9.10.1016/S0190-9622(97)70174-99344196Haber R.S., Weiser K.R., Pritsker A., Reder I., Burstein D.E. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid Off. J. Am. Thyroid Assoc. 1997;7:363–367. doi: 10.1089/thy.1997.7.363.10.1089/thy.1997.7.3639226204Grover-McKay M., Walsh S.A., Seftor E.A., Thomas P.A., Hendrix M.J. Role for glucose transporter 1 protein in human breast cancer. Pathol. Oncol. Res. POR. 1998;4:115–120. doi: 10.1007/BF02904704.10.1007/BF029047049654596Oran Kwon P.E., Chen S., Corpe C., Lee J.H., Kruhlak M., Levine M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J. 2007;21:366–377. doi: 10.1096/fj.06-6620com.10.1096/fj.06-6620com17172639Michele Skopec A.G., Karasov W. Flavonoids have differential effects on the glucose absorption in rats and american robins. J. Chem. Ecol. 2010;36:236–243. doi: 10.1007/s10886-010-9747-9.10.1007/s10886-010-9747-920145981Cheeseman C.I. Glut2 Is the Transporter for Fructose across the Rat Intestinal Basolateral Membrane. Gastroenterology. 1993;105:1050–1056. doi: 10.1016/0016-5085(93)90948-C.10.1016/0016-5085(93)90948-C8405848Johnson J.H., Newgard C.B., Milburn J.L., Lodish H.F., Thorens B. The High Km Glucose Transporter of Islets of Langerhans Is Functionally Similar to the Low Affinity Transporter of Liver and Has an Identical Primary Sequence. J. Biol. Chem. 1990;265:6548–6551. doi: 10.1016/S0021-9258(19)39181-1.10.1016/S0021-9258(19)39181-12182619Colville C.A., Seatter M.J., Jess T.J., Gould G.W., Thomas H.M. Kinetic-Analysis of the Liver-Type (Glut2) and Brain-Type (Glut3) Glucose Transporters in Xenopus Oocytes—Substrate Specificities and Effects of Transport Inhibitors. Biochem. J. 1993;290:701–706. doi: 10.1042/bj2900701.10.1042/bj2900701PMC11323378457197Goto T., Horita M., Nagai H., Nagatomo A., Nishida N., Matsuura Y., Nagaoka S. Tiliroside, a glycosidic flavonoid, inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract. Mol. Nutr. Food Res. 2012;56:435–445. doi: 10.1002/mnfr.201100458.10.1002/mnfr.20110045822173993Maher F., Davies-Hill T.M., Lysko P.G., Henneberry R.C., Simpson I.A. Expression of two glucose transporters, GLUT1 and GLUT3, in cultured cerebellar neurons: Evidence for neuron-specific expression of GLUT3. Mol. Cell. Neurosci. 1991;2:351–360. doi: 10.1016/1044-7431(91)90066-W.10.1016/1044-7431(91)90066-W19912819Zeller K., Duelli R., Vogel J., Schrock H., Kuschinsky W. Autoradiographic Analysis of the Regional Distribution of Glut3 Glucose Transporters in the Rat-Brain. Brain Res. 1995;698:175–179. doi: 10.1016/0006-8993(95)00888-W.10.1016/0006-8993(95)00888-W8581478Mccall A.L., Vanbueren A.M., Moholtsiebert M., Cherry N.J., Woodward W.R. Immunohistochemical Localization of the Neuron-Specific Glucose-Transporter (Glut3) to Neuropil in Adult-Rat Brain. Brain Res. 1994;659:292–297. doi: 10.1016/0006-8993(94)90896-6.10.1016/0006-8993(94)90896-67820678Simpson I.A., Dwyer D., Malide D., Moley K.H., Travis A., Vannucci S.J. The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol. Endocrinol. Metab. 2008;295:E242–E253. doi: 10.1152/ajpendo.90388.2008.10.1152/ajpendo.90388.2008PMC251975718577699Arbuckle M.I., Kane S., Porter L.M., Seatter M.J., Gould G.W. Structure-function analysis of liver-type (GLUT2) and brain-type (GLUT3) glucose transporters: Expression of chimeric transporters in Xenopus oocytes suggests an important role for putative transmembrane helix 7 in determining substrate selectivity. Biochemistry. 1996;35:16519–16527. doi: 10.1021/bi962210n.10.1021/bi962210n8987985Masin M., Vazquez J., Rossi S., Groeneveld S., Samson N., Schwalie P.C., Deplancke B., Frawley L.E., Gouttenoire J., Moradpour D., et al. GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer Metab. 2014;2:11. doi: 10.1186/2049-3002-2-11.10.1186/2049-3002-2-11PMC412205425097756Baer S., Casaubon L., Schwartz M.R., Marcogliese A., Younes M. Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope. 2002;112:393–396. doi: 10.1097/00005537-200202000-00034.10.1097/00005537-200202000-0003411889403Flavahan W.A., Wu Q.L., Hitomi M., Rahim N., Kim Y., Sloan A.E., Weil R.J., Nakano I., Sarkaria J.N., Stringer B.W., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 2013;16:1373–1382. doi: 10.1038/nn.3510.10.1038/nn.3510PMC393017723995067Bell G.I., Murray J.C., Nakamura Y., Kayano T., Eddy R.L., Fan Y.S., Byers M.G., Shows T.B. Polymorphic human insulin-responsive glucose-transporter gene on chromosome 17p13. Diabetes. 1989;38:1072–1075. doi: 10.2337/diab.38.8.1072.10.2337/diab.38.8.10722568955Huang S.H., Czech M.P. The GLUT4 glucose transporter. Cell Metab. 2007;5:237–252. doi: 10.1016/j.cmet.2007.03.006.10.1016/j.cmet.2007.03.00617403369Burant C.F., Bell G.I. Mammalian Facilitative Glucose Transporters—Evidence for Similar Substrate Recognition Sites in Functionally Monomeric Proteins. Biochemistry. 1992;31:10414–10420. doi: 10.1021/bi00157a032.10.1021/bi00157a0321420159Gupta P., Kanwal A., Putcha U.K., Bulani Y., Sojitra B., Khatua T.N., Kuncha M., Banerjee S.K. Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: A new therapeutic implication. J. Transl. Med. 2013;11:80. doi: 10.1186/1479-5876-11-80.10.1186/1479-5876-11-80PMC362374423531330Kouidhi S., Berrhouma R., Rouissi K., Jarboui S., Clerget-Froidevaux M.S., Seugnet I., Bchir F., Demeneix B., Guissouma H., Elgaaied A.B. Human subcutaneous adipose tissue Glut 4 mRNA expression in obesity and type 2 diabetes. Acta Diabetol. 2013;50:227–232. doi: 10.1007/s00592-011-0295-8.10.1007/s00592-011-0295-821604201Wu X.H., Freeze H.H. GLUT14, a duplicon of GLUT3, is specifically expressed in testis as alternative splice forms. Genomics. 2002;80:553–557. doi: 10.1006/geno.2002.7010.10.1006/geno.2002.701012504846Welch R.D., Gorski J. Regulation of glucose transporters by estradiol in the immature rat uterus. Endocrinology. 1999;140:3602–3608. doi: 10.1210/endo.140.8.6923.10.1210/endo.140.8.692310433217von Wolff M., Ursel S., Hahn U., Steldinger R., Strowitzki T. Glucose transporter proteins (GLUT) in human endometrium: Expression, regulation, and function throughout the menstrual cycle and in early pregnancy. J. Clin. Endocr. Metab. 2003;88:3885–3892. doi: 10.1210/jc.2002-021890.10.1210/jc.2002-02189012915684Inukai K., Katagiri H., Takata K., Asano T., Anai M., Ishihara H., Nakazaki M., Kikuchi M., Yazaki Y., Oka Y. Characterization of Rat Glut5 and Functional-Analysis of Chimeric Proteins of Glut1 Glucose-Transporter and Glut5 Fructose Transporter. Endocrinology. 1995;136:4850–4857. doi: 10.1210/endo.136.11.7588216.10.1210/endo.136.11.75882167588216Burant C.F., Takeda J., Brotlaroche E., Bell G.I., Davidson N.O. Fructose Transporter in Human Spermatozoa and Small-Intestine Is Glut5. J. Biol. Chem. 1992;267:14523–14526. doi: 10.1016/S0021-9258(18)42067-4.10.1016/S0021-9258(18)42067-41634504McQuade D.T., Plutschack M.B., Seeberger P.H. Passive fructose transporters in disease: A molecular overview of their structural specificity. Org. Biomol. Chem. 2013;11:4909–4920. doi: 10.1039/c3ob40805a.10.1039/c3ob40805a23784005Tatibouet A., Yang J., Morin C., Holman G.D. Synthesis and evaluation of fructose analogues as inhibitors of the D-fructose transporter GLUT5. Bioorganic Med. Chem. 2000;8:1825–1833. doi: 10.1016/S0968-0896(00)00108-5.10.1016/S0968-0896(00)00108-510976531Yang J., Tatibouet A., Hatanaka Y., Holman G.D. Fructose analogues with enhanced affinity for GLUT5. Diabetes. 2001;50:A277.Yang J., Dowden J., Tatibouet A., Hatanaka Y., Holman G.D. Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5. Biochem. J. 2002;367:533–539. doi: 10.1042/bj20020843.10.1042/bj20020843PMC122289912119043Tanasova M., Fedie J. Molecular Tools for Facilitative Carbohydrate Transporters. ChemBioChem. 2017;18:1774–1788. doi: 10.1002/cbic.201700221.10.1002/cbic.20170022128636761Li Q., Manolescu A., Ritzel M., Yao S., Slugoski M., Young J.D., Chen X.Z., Cheeseman C.I. Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am. J. Physiol. Gastrointestin. Liver Physiol. 2004;287:G236–G242. doi: 10.1152/ajpgi.00396.2003.10.1152/ajpgi.00396.200315033637Doege H., Bocianski A., Scheepers A., Axer H., Eckel J., Joost H.G., Schurmann A. Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. Biochem. J. 2001;359:443–449. doi: 10.1042/bj3590443.10.1042/bj3590443PMC122216511583593Augustin R., Carayannopoulos M.O., Dowd L.O., Phay J.E., Moley J.F., Moley K.H. Identification and characterization of human glucose transporter-like protein-9 (GLUT9)—Alternative splicing alters trafficking. J. Biol. Chem. 2004;279:16229–16236. doi: 10.1074/jbc.M312226200.10.1074/jbc.M31222620014739288Scheepers A., Schmidt S., Manolescu A., Cheeseman C.I., Bell A., Zahn C., Joost H.G., Schurmann A. Characterization of the human SLC2A11 (GLUT11) gene: Alternative promoter usage, function, expression, and subcellular distribution of three isoforms, and lack of mouse orthologue. Mol. Membr. Biol. 2005;22:339–351. doi: 10.1080/09687860500166143.10.1080/0968786050016614316154905Ibberson M., Uldry M., Thorens B. GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J. Biol. Chem. 2000;275:4607–4612. doi: 10.1074/jbc.275.7.4607.10.1074/jbc.275.7.460710671487Rogers S., Macheda M.L., Docherty S.E., Carty M.D., Henderson M.A., Soeller W.C., Gibbs E.M., James D.E., Best J.D. Identification of a novel glucose transporter-like protein-GLUT-12. Am. J. Physiol. Endocrinol. Metab. 2002;282:E733–E738. doi: 10.1152/ajpendo.2002.282.3.E733.10.1152/ajpendo.2002.282.3.E73311832379Ibberson M., Riederer B.M., Uldry M., Guhl B., Roth J., Thorens B. Immunolocalization of GLUTX1 in the testis and to specific brain areas and vasopressin-containing neurons. Endocrinology. 2002;143:276–284. doi: 10.1210/endo.143.1.8587.10.1210/endo.143.1.858711751619Gawlik V., Schmidt S., Scheepers A., Wennemuth G., Augustin R., Aumuller G., Moser M., Al-Hasani H., Kluge R., Joost H.G., et al. Targeted disruption of Slc2a8 (GLUT8) reduces motility and mitochondrial potential of spermatozoa. Mol. Membr. Biol. 2008;25:224–235. doi: 10.1080/09687680701855405.10.1080/09687680701855405PMC255707018428038Zhao F.Q., Miller P.J., Wall E.H., Zheng Y.C., Dong B., Neville M.C., McFadden T.B. Bovine glucose transporter GLUT8: Cloning, expression, and developmental regulation in mammary gland. BBA-Gene Struct. Expr. 2004;1680:103–113. doi: 10.1016/j.bbaexp.2004.09.001.10.1016/j.bbaexp.2004.09.00115488990Carayannopoulos M.O., Chi M.M., Cui Y., Pingsterhaus J.M., McKnight R.A., Mueckler M., Devaskar S.U., Moley K.H. GLUT8 is a glucose transporter responsible for insulin-stimulated glucose uptake in the blastocyst. Proc. Natl. Acad. Sci. USA. 2000;97:7313–7318. doi: 10.1073/pnas.97.13.7313.10.1073/pnas.97.13.7313PMC1654210860996Lisinski I., Schurmann A., Joost H.G., Cushman S.W., Al-Hasani H. Targeting of GLUT6 (formerly GLUT9) and GLUT8 in rat adipose cells. Biochem. J. 2001;358:517–522. doi: 10.1042/bj3580517.10.1042/bj3580517PMC122208711513753Piroli G.G., Grillo C.A., Hoskin E.K., Znamensky V., Katz E.B., Milner T.A., McEwen B.S., Charron M.J., Reagan L.P. Peripheral glucose administration stimulates the translocation of GLUT8 glucose transporter to the endoplasmic reticulum in the rat hippocampus. J. Comp. Neurol. 2002;452:103–114. doi: 10.1002/cne.10368.10.1002/cne.1036812271485Rogers S., Docherty S.E., Slavin J.L., Henderson M.A., Best J.D. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 2003;193:225–233. doi: 10.1016/S0304-3835(03)00010-7.10.1016/S0304-3835(03)00010-712706881Uldry M., Ibberson M., Horisberger J.D., Chatton J.Y., Riederer B.M., Thorens B. Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 2001;20:4467–4477. doi: 10.1093/emboj/20.16.4467.10.1093/emboj/20.16.4467PMC12557411500374Goran M.I., Ulijaszek S.J., Ventura E.E. High fructose corn syrup and diabetes prevalence: A global perspective. Glob. Publ. Health. 2013;8:55–64. doi: 10.1080/17441692.2012.736257.10.1080/17441692.2012.73625723181629Nomura K., Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2012;23:203–208. doi: 10.1016/j.jnutbio.2011.09.006.10.1016/j.jnutbio.2011.09.00622129639Gaby A.R. Adverse effects of dietary fructose. Altern. Med. Rev. 2005;10:294–306.16366738Fan X.J., Liu H.R., Liu M., Wang Y.Y., Qiu L., Cui Y.F. Increased utilization of fructose has a positive effect on the development of breast cancer. PEER J. 2017;5:e3804. doi: 10.7717/peerj.3804.10.7717/peerj.3804PMC562260528970966Liu H.B., Huang D.S., McArthur D.L., Boros L.G., Nissen N., Heaney A.P. Fructose Induces Transketolase Flux to Promote Pancreatic Cancer Growth. Cancer Res. 2010;70:6368–6376. doi: 10.1158/0008-5472.CAN-09-4615.10.1158/0008-5472.CAN-09-461520647326Carvalho K.C., Cunha I.W., Rocha R.M., Ayala F.R., Cajaiba M.M., Begnami M.D., Vilela R.S., Paiva G.R., Andrade R.G., Soares F.A. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics. 2011;66:965–972. doi: 10.1590/S1807-59322011000600008.10.1590/S1807-59322011000600008PMC312995821808860Goodwin J., Neugent M.L., Lee S.Y., Choe J.H., Choi H., Jenkins D.M.R., Ruthenborg R.J., Robinson M.W., Jeong J.Y., Wake M., et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat. Commun. 2017;8:15503. doi: 10.1038/ncomms15503.10.1038/ncomms15503PMC545856128548087Kayano T., Fukumoto H., Eddy R.L., Fan Y.S., Byers M.G., Shows T.B., Bell G.I. Evidence for a Family of Human Glucose Transporter-Like Proteins—Sequence and Gene Localization of a Protein Expressed in Fetal Skeletal-Muscle and Other Tissues. J. Biol. Chem. 1988;263:15245–15248. doi: 10.1016/S0021-9258(19)37577-5.10.1016/S0021-9258(19)37577-53170580Zamora-Leon S.P., Golde D.W., Concha I.I., Rivas C.I., DelgadoLopez F., Baselga J., Nualart F., Vera J.C. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA. 1996;93:1847–1852. doi: 10.1073/pnas.93.5.1847.10.1073/pnas.93.5.1847PMC398708700847Trayner B.J., Grant T.N., West F.G., Cheeseman C.I. Synthesis and characterization of 6-deoxy-6-fluoro-D-fructose as a potential compound for imaging breast cancer with PET. Bioorganic Med. Chem. 2009;17:5488–5495. doi: 10.1016/j.bmc.2009.06.034.10.1016/j.bmc.2009.06.03419586773Bono Y., Mizumoto Y., Nakamura M., Iwadare J., Obata T., Fujiwara H. FDG-PET-positive ovarian thecoma with GLUT5 expression: Five cases. J. Obstet. Gynaecol. Res. 2016;43:599–603. doi: 10.1111/jog.13243.10.1111/jog.1324327987341Wolin K.Y., Carson K., Colditz G.A. Obesity and Cancer. Oncologist. 2010;15:556–565. doi: 10.1634/theoncologist.2009-0285.10.1634/theoncologist.2009-0285PMC322798920507889Rowlands M.A., Gunnell D., Harris R., Vatten L.J., Holly J.M., Martin R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int. J. Cancer. 2009;124:2416–2429. doi: 10.1002/ijc.24202.10.1002/ijc.24202PMC274303619142965Gallagher E.J., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrin. Met. 2010;21:610–618. doi: 10.1016/j.tem.2010.06.007.10.1016/j.tem.2010.06.007PMC294948120663687Graham N.A., Tahmasian M., Kohli B., Komisopoulou E., Zhu M.G., Vivanco I., Teitell M.A., Wu H., Ribas A., Lo R.S., et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol. Syst. Biol. 2012;8:589–904. doi: 10.1038/msb.2012.20.10.1038/msb.2012.20PMC339741422735335Xie L.L., Wang W.Q. Weight control and cancer preventive mechanisms: Role of insulin growth factor-1-mediated signaling pathways. Exp. Biol. Med. 2013;238:127–132. doi: 10.1177/1535370213477602.10.1177/1535370213477602PMC404906823576795Raffaghello L., Lee C., Safdie F.M., Wei M., Madia F., Bianchi G., Longo V.D. Starvation-dependent differential stress resistance protects normal but not cancer COS against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA. 2008;105:8215–8220. doi: 10.1073/pnas.0708100105.10.1073/pnas.0708100105PMC244881718378900Allen B.G., Bhatia S.K., Anderson C.M., Eichenberger-Gilmore J.M., Sibenaller Z.A., Mapuskar K.A., Schoenfeld J.D., Buatti J.M., Spitz D.R., Fath M.A. Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox. Biol. 2014;2:963–970. doi: 10.1016/j.redox.2014.08.002.10.1016/j.redox.2014.08.002PMC421547225460731Granchi C., Fortunato S., Minutolo F. Anticancer agents interacting with membrane glucose transporters. Medchemcomm. 2016;7:1716–1729. doi: 10.1039/C6MD00287K.10.1039/C6MD00287KPMC519891028042452Tanasova M., Begoyan V.V., Weselinski L.J. Targeting Sugar Uptake and Metabolism for Cancer Identification and Therapy: An Overview. Curr. Top. Med. Chem. 2018;18:467–483. doi: 10.2174/1568026618666180523110837.10.2174/156802661866618052311083729788891Boel A., Burger J., Vanhomwegen M., Beyens A., Renard M., Barnhoorn S., Casteleyn C., Reinhardt D.P., Descamps B., Vanhove C., et al. Slc2a10 knock-out mice deficient in ascorbic acid synthesis recapitulate aspects of arterial tortuosity syndrome and display mitochondrial respiration defects. Hum. Mol. Genet. 2020;29:1476–1488. doi: 10.1093/hmg/ddaa071.10.1093/hmg/ddaa07132307537Shi Y., Zhang Y., Ran F., Liu J., Lin J., Hao X., Ding L., Ye Q. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect. Cancer Lett. 2020;495:53–65. doi: 10.1016/j.canlet.2020.09.012.10.1016/j.canlet.2020.09.01232946964Jacquier V., Gitenay D., Fritsch S., Bonnet S., Győrffy B., Jalaguier S., Linares L.K., Cavaillès V., Teyssier C. RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53. Cell. Mol. Life Sci. CMLS. 2022;79:270. doi: 10.1007/s00018-022-04277-3.10.1007/s00018-022-04277-3PMC906169635501580Włodarczyk J., Włodarczyk M., Zielińska M., Jędrzejczak B., Dziki Ł., Fichna J. Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: Proof of concept for a new class of anti-tumor therapeutics. Pharmacol. Rep. 2021;73:939–945. doi: 10.1007/s43440-021-00281-9.10.1007/s43440-021-00281-9PMC818047834052986Shen Z., Li Z., Liu Y., Li Y., Feng X., Zhan Y., Lin M., Fang C., Fang Y., Deng H. GLUT5-KHK axis-mediated fructose metabolism drives proliferation and chemotherapy resistance of colorectal cancer. Cancer Lett. 2022;534:215617. doi: 10.1016/j.canlet.2022.215617.10.1016/j.canlet.2022.21561735257833Caruana B.T., Byrne F.L. The NF-κB signalling pathway regulates GLUT6 expression in endometrial cancer. Cell. Signal. 2020;73:109688. doi: 10.1016/j.cellsig.2020.109688.10.1016/j.cellsig.2020.10968832512041Zeng Z., Nian Q., Chen N., Zhao M., Zheng Q., Zhang G., Zhao Z., Chen Y., Wang J., Zeng J., et al. Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4. Biomed. Pharmacother. 2022;145:112086. doi: 10.1016/j.biopha.2021.112086.10.1016/j.biopha.2021.11208634799220Fu M., Liu Y., Cheng H., Xu K., Wang G. Coptis chinensis and dried ginger herb combination inhibits gastric tumor growth by interfering with glucose metabolism via LDHA and SLC2A1. J. Ethnopharmacol. 2022;284:114771. doi: 10.1016/j.jep.2021.114771.10.1016/j.jep.2021.11477134737010Bai Y., Ye B., Li T., Wang R., Qi X. H22954, a long non-coding RNA, inhibits glucose uptake in leukemia cells in a GLUT10-dependent manner. Hematology. 2022;27:469–475. doi: 10.1080/16078454.2022.2061112.10.1080/16078454.2022.206111235413230Olszewski K., Barsotti A., Feng X.-J., Momcilovic M., Liu K.G., Kim J.-I., Morris K., Lamarque C., Gaffney J., Yu X., et al. Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors. Cell Chem. Biol. 2022;29:423–435.e410. doi: 10.1016/j.chembiol.2021.10.007.10.1016/j.chembiol.2021.10.00734715056Hayashi K., Noguchi-Shinohara M., Sato T., Hosomichi K., Kannon T., Abe C., Domoto C., Yuki-Nozaki S., Mori A., Horimoto M., et al. Effects of functional variants of vitamin C transporter genes on apolipoprotein E E4-associated risk of cognitive decline: The Nakajima study. PLoS ONE. 2021;16:e0259663. doi: 10.1371/journal.pone.0259663.10.1371/journal.pone.0259663PMC859248334780525Basu S., Liu C., Zhou X.K., Nishiguchi R., Ha T., Chen J., Johncilla M., Yantiss R.K., Montrose D.C., Dannenberg A.J. GLUT5 is a determinant of dietary fructose-mediated exacerbation of experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2021;321:G232–G242. doi: 10.1152/ajpgi.00059.2021.10.1152/ajpgi.00059.202134133236Sun Y., Lu L., Li L., Wang J. An advance about the genetic causes of epilepsy. E3S Web Conf. 2021;271:03068. doi: 10.1051/e3sconf/202127103068.10.1051/e3sconf/202127103068Patanè F., Pasquetti E., Sullo F., Tosto M., Romano C., Salafia S., Falsaperla R. SLC2A1 and Its Related Epileptic Phenotypes. J. Pediatric Neurol. 2022 doi: 10.1055/s-0041-1728668.10.1055/s-0041-1728668Lee H., Kim E., Shin E.-A., Shon J.C., Sun H., Kim J.E., Jung J.W., Lee H., Pinanga Y., Song D.-G., et al. Crosstalk between TM4SF5 and GLUT8 regulates fructose metabolism in hepatic steatosis. Mol. Metab. 2022;58:101451. doi: 10.1016/j.molmet.2022.101451.10.1016/j.molmet.2022.101451PMC886666935123128Wu Z., Wen Y., Fan G., He H., Zhou S., Chen L. HEMGN and SLC2A1 might be potential diagnostic biomarkers of steroid-induced osteonecrosis of femoral head: Study based on WGCNA and DEGs screening. BMC Musculoskelet. Disord. 2021;22:85. doi: 10.1186/s12891-021-03958-7.10.1186/s12891-021-03958-7PMC781121933451334Shi Y.-L., Zhang Y.-P., Luo H., Xu F., Gao J.-M., Shi J.-S., Gong Q.-H. Trilobatin, a Natural Food Additive, Exerts Anti-Type 2 Diabetes Effect Mediated by Nrf2/ARE and IRS-1/GLUT2 Signaling Pathways. Front. Pharmacol. 2022;13:828473. doi: 10.3389/fphar.2022.828473.10.3389/fphar.2022.828473PMC882903535153796Ye X., Chen W., Tu P., Jia R., Liu Y., Tang Q., Chen C., Yang C., Zheng X., Chu Q. Antihyperglycemic effect of an anthocyanin, cyanidin-3-O-glucoside, is achieved by regulating GLUT-1 via the Wnt/β-catenin-WISP1 signaling pathway. Food Funct. 2022;13:4612–4623. doi: 10.1039/D1FO03730G.10.1039/D1FO03730G35357376Shao R., Liao X., Lan Y., Zhang H., Jiao L., Du Q., Han D., Ai Q., Mai K., Wan M. Vitamin D regulates insulin pathway and glucose metabolism in zebrafish (Danio rerio) FASEB J. 2022;36:e22330. doi: 10.1096/fj.202200334RR.10.1096/fj.202200334RR35474468